Bioventix PLC
LSE:BVXP

Watchlist Manager
Bioventix PLC Logo
Bioventix PLC
LSE:BVXP
Watchlist
Price: 3 170 GBX -4.66% Market Closed
Market Cap: 165.5m GBX
Have any thoughts about
Bioventix PLC?
Write Note

Operating Margin
Bioventix PLC

79.1%
Current
78%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
79.1%
=
Operating Profit
10.8m
/
Revenue
13.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Bioventix PLC
LSE:BVXP
165.5m GBP
79%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
311.8B USD
28%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country UK
Market Cap 165.5m GBP
Operating Margin
79%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 311.8B USD
Operating Margin
28%
Country US
Market Cap 140.7B USD
Operating Margin
19%
Country US
Market Cap 115.7B USD
Operating Margin
38%
Country US
Market Cap 102.7B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Bioventix PLC
Glance View

Market Cap
165.5m GBX
Industry
Biotechnology

Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 17 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm also supplies antibody products and services to multinational clinical diagnostics companies. The firm sells its products through direct sales and through distributors.

BVXP Intrinsic Value
3 026.52 GBX
Overvaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
79.1%
=
Operating Profit
10.8m
/
Revenue
13.6m
What is the Operating Margin of Bioventix PLC?

Based on Bioventix PLC's most recent financial statements, the company has Operating Margin of 79.1%.